Monitor upcoming clinical data readouts for FHD-909, particularly the Phase 1 monotherapy data expected in 2026, as the strong preclinical results suggest potential for clinical efficacy in SMARCA4-mutant cancers.
FHTX drugs
FHTX drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 22 $5.39entry
- T+1 · 7mo ago −3.71%α −3.32% · $5.19
- T+5 · 7mo ago −9.09%α −9.15% · $4.90
- T+20 · 6mo ago −33.21%α −36.38% · $3.60
- T+60 · 4mo ago −3.71%α −8.49% · $5.19
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Foghorn Therapeutics presented new preclinical data at AACR 2026 showing promising results across its pipeline, including complete tumor regression with FHD-909 in combination with anti-PD1 and strong efficacy in multiple degrader programs. The company also announced its ongoing collaboration with Lilly.
Key Facts
- FHD-909 in combination with anti-PD1 demonstrated complete and durable tumor regression in preclinical models
- Selective CBP degrader FHT-171 showed strong anti-tumor activity in ER+ breast cancer models
- Selective EP300 degrader outperformed clinical benchmark in multiple myeloma models
- Robust degradation achieved with cereblon-based selective ARID1B degraders
- Company has $158.9 million in cash and equivalents as of December 31, 2025
Financial Impact
The company has $158.9 million in cash and equivalents as of December 31, 2025, with $50 million gross proceeds from a January 2026 financing
Risk Factors
- Preclinical results may not translate to human clinical trials
- The company is still in early stages of development with no approved products
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-026259 |
| Exhibit: exhibit992foghornaacrpress.htm | 0001628280-26-026259 |
| Document: fhtx-20260421.htm | 0001628280-26-026259 |
| Document: 0001628280-26-026259-index-headers.html | 0001628280-26-026259 |
| Document: 0001628280-26-026259-index.html | 0001628280-26-026259 |
| Document: 0001628280-26-026259.txt | 0001628280-26-026259 |
Track record
9 reports on FHTX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today Institutional Cluster Neutral 3/10 Entry $1.81 Now $1.79 −0.83% settles Dec 15
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $2.04 Now $1.79 −12.25% settles Dec 8
- Oct 5, 20266w ago 3 Neutral 2/10 Entry $1.97 to $2.12 Now $1.79 −9.14% ▲ +7.36% +10.26% vs SPY
- Oct 5, 20266w ago SC 13G/A Neutral 4/10 Entry $1.97 to $2.13 Now $1.79 −9.14% ▲ +8.12% +11.30% vs SPY
- Oct 1, 20266w ago 8-K Bearish 7/10 Entry $2.92 to $2.09 Now $1.79 +38.70% ▲ +28.42% +29.13% vs SPY
- Aug 6, 202614w ago 8-K Mixed 5/10 Entry $5.57 to $4.87 Now $1.79 −67.86% ▼ −12.57% −13.17% vs SPY
- May 7, 202627w ago 8-K Neutral 3/10 Entry $4.20 to $3.64 Now $1.79 −57.38% ▼ −13.33% −16.47% vs SPY
- Apr 21, 202629w ago Press Release Bullish 7/10 Entry $5.39 to $3.60 Now $1.79 −66.79% ▼ −33.21% −36.38% vs SPY
- Apr 21, 202629w ago 8-K Bullish 7/10 Viewing Entry $5.39 to $3.60 Now $1.79 −66.79% ▼ −33.21% −36.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers